Identification

Name
Doxycycline
Accession Number
DB00254  (APRD00597)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum).

Structure
Thumb
Synonyms
  • 5-hydroxy-α-6-deoxytetracycline
  • 6-alpha-deoxy-5-oxytetracycline
  • 6alpha-deoxy-5-oxytetracycline
  • 6α-deoxy-5-oxytetracycline
  • Anhydrous doxycycline
  • Doxiciclina
  • Doxycyclin
  • Doxycycline (anhydrous)
  • Doxycycline anhydrous
  • Doxycyclinum
Product Ingredients
IngredientUNIICASInChI Key
Doxycycline calcium8ZL07I20SB94088-85-4IYECPECUTCOMMD-QFWOMMJSSA-N
Doxycycline hyclate19XTS3T51U24390-14-5HALQELOKLVRWRI-VDBOFHIQSA-N
Doxycycline hydrochloride4182Z6T2ET10592-13-9RUYHIJHUVHIMIR-CVHRZJFOSA-N
Doxycycline monohydrateN12000U13O17086-28-1XQTWDDCIUJNLTR-CVHRZJFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActiclateTablet, coated150 mg/1OralAqua Pharmaceuticals2014-07-28Not applicableUs
ActiclateTablet, coated75 mg/1OralAqua Pharmaceuticals2014-07-28Not applicableUs
Acticlate CAPCapsule75 mg/1OralAqua Pharmaceuticals2018-05-31Not applicableUs
Apprilon40 mgOralGalderma2012-11-29Not applicableCanada
AtridoxKit50 mg/1OralDen-mat Holdings, Llc2016-12-01Not applicableUs
AtridoxKit50 mg/500mgOralTOLMAR Inc.1998-09-03Not applicableUs
Atridox8.8 %OralTolmar Inc2001-01-31Not applicableCanada
DoryxTablet, delayed release150 mg/1OralAllergan2011-09-212013-01-31Us00430 0115 20 nlmimage10 e63af317
DoryxCapsule, delayed release pellets100 mg/1OralPhysicians Total Care, Inc.1985-07-222000-09-19Us
DoryxTablet, delayed release200 mg/1OralMayne Pharma2015-04-13Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdoxaCapsule150 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2011-06-01Not applicableUs10337 0815 06 nlmimage10 7203b95d
AlodoxTablet20 mg/1OralO Cu Soft, Inc.2008-10-01Not applicableUs
Alti-doxycycline - Tab 100mgTablet100 mgOralAltimed Pharma Inc.1995-12-312001-09-05Canada
Alti-doxycycline-cap 100mgCapsule100 mgOralAltimed Pharma Inc.1995-12-312001-09-05Canada
Apo-doxy Cap 100mgCapsule100 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-doxy Tabs 100mgTablet100 mgOralApotex Corporation1990-12-31Not applicableCanada
Dom-doxycyclineCapsule100 mgOralDominion Pharmacal2008-04-162016-10-25Canada
Dom-doxycyclineTablet100 mgOralDominion Pharmacal2008-04-162016-10-25Canada
Doxy 100Injection, powder, lyophilized, for solution100 mg/10mLIntravenousFresenius Kabi2000-10-17Not applicableUs
Doxy 100Injection, powder, lyophilized, for solution100 mg/10mLIntravenousGeneral Injectables & Vaccines2012-02-22Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BenoxylDoxy 30 KitDoxycycline monohydrate (100 mg/1) + Benzoyl peroxide (44 mg/1mL)KitElorac, Inc.2014-07-012014-08-07Us
BenoxylDoxy 60 KitDoxycycline monohydrate (100 mg/1) + Benzoyl peroxide (44 mg/1mL)KitElorac, Inc.2014-07-012015-07-18Us
BenzoDox 30 KitDoxycycline monohydrate (100 mg/1) + Benzoyl peroxide (44 mg/1mL)KitElorac, Inc.2015-10-01Not applicableUs
BenzoDox 60 KitDoxycycline monohydrate (100 mg/1) + Benzoyl peroxide (44 mg/1mL)KitElorac, Inc.2015-09-22Not applicableUs
NicAzel Doxy KitDoxycycline monohydrate (100 mg/1) + Cupric oxide (2 mg/1) + Folic Acid (500 ug/1) + Pyridoxine (8 mg/1) + Zinc oxide (12 mg/1)KitElorac, Inc.2014-06-302015-07-30Us
International/Other Brands
Doxy (Galpharma) / Doxycin (Laboratoire Riva) / Doxylin (Actavis) / Jenacyclin / Microdox (Micro Labs) / NicAzelDoxyKit / Nu-Doxycycline (Nu-Pharm) / Supracyclin (Grünenthal) / Vibramycin (Pfizer)
Categories
UNII
334895S862
CAS number
564-25-0
Weight
Average: 444.4346
Monoisotopic: 444.153265754
Chemical Formula
C22H24N2O8
InChI Key
JBIWCJUYHHGXTC-AKNGSSGZSA-N
InChI
InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
IUPAC Name
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O

Pharmacology

Indication

Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

Associated Conditions
Pharmacodynamics

Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.

Mechanism of action

Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.

TargetActionsOrganism
A30S ribosomal protein S9
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S4
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UProtein-arginine deiminase type-4Not AvailableHuman
UBeta-2-microglobulinNot AvailableHuman
Absorption

Completely absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

>90%

Metabolism

Hepatic

Route of elimination

They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.

Half life

18-22 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).

Affected organisms
  • Enteric bacteria and other eubacteria
  • Treponema pallidum
  • Leptospira interrogans
  • Clostridium perfringens
  • Borrelia burgdorferi
  • Brucella abortus
  • Brucella canis
  • Chlamydia pneumoniae
  • Chlamydia trachomatis
  • Helicobacter pylori
  • Mycoplasma pneumoniae
  • Neisseria gonorrhoeae
  • Rickettsia rickettsii
  • Vibrio cholerae
  • Yersinia pestis
  • Chlamydia psittaci
Pathways
PathwayCategory
Doxycycline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Doxycycline.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Doxycycline.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Doxycycline.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Doxycycline.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Doxycycline.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Doxycycline.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be decreased when combined with Doxycycline.
AbacavirDoxycycline may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Doxycycline.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Doxycycline.
Food Interactions
  • Avoid alcohol.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.

References

Synthesis Reference

Dai-Wu Seol, "DNA cassette for the production of secretable recombinant trimeric TRAIL proteins, tetracycline/ doxycycline-inducible adeno-associated virus vector, their combination and use in gene therapy." U.S. Patent US20020128438, issued September 12, 2002.

US20020128438
General References
  1. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ: Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006 Sep;50(9):3124-31. [PubMed:16940111]
  2. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5. [PubMed:12684759]
  3. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21. [PubMed:15964448]
External Links
Human Metabolome Database
HMDB0014399
KEGG Drug
D07876
KEGG Compound
C06973
PubChem Compound
54671203
PubChem Substance
46506491
ChemSpider
10469369
BindingDB
50041429
ChEBI
50845
ChEMBL
CHEMBL1433
Therapeutic Targets Database
DAP001371
PharmGKB
PA449415
HET
DXT
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxycycline
ATC Codes
A01AB22 — DoxycyclineJ01AA20 — Combinations of tetracyclinesJ01AA02 — Doxycycline
AHFS Codes
  • 08:12.24 — Tetracyclines
PDB Entries
2o7o / 2xrl / 5om2 / 5om3
FDA label
Download (48.1 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionSexually Transmitted Infections (STIs) / Syphilis1
0RecruitingOtherCutaneous Rosacea / Ocular Rosacea / Rosaceas1
0RecruitingTreatmentLymphoma, T-Cell, Cutaneous1
0RecruitingTreatmentMalignant Neoplasms of Respiratory and Intrathoracic Organs1
0RecruitingTreatmentOsteomyelitis1
1Active Not RecruitingPreventionCardiorenal Syndrome / Chronic Kidney Disease (CKD)1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions3
1CompletedBasic ScienceBacterial Infections / Healthy Volunteers / Infections, Fungal1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherTo Determine Bioequivalence Under Fed Conditions2
1CompletedPreventionArteriovenous Malformations / Brain Aneurysms / Cavernous Angiomas1
1CompletedTreatmentAneurysms / Arteriovenous Malformations1
1RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract1
1TerminatedTreatmentAnthrax1
1, 2Active Not RecruitingHealth Services ResearchAcne Vulgaris1
1, 2CompletedTreatmentAmyloidosis; Heart (Manifestation) / Senile Cardiac Amyloidosis1
1, 2CompletedTreatmentAutoimmune Diseases / Endocrine System Diseases / Eye Diseases / Eye Diseases, Hereditary / Graves Diseases / Graves Ophthalmopathy / Hyperthyroidism / Immune System Diseases / Thyroid Diseases1
1, 2CompletedTreatmentPeriodontitis, Aggressive1
1, 2TerminatedTreatmentDiabetic Foot Ulcers (DFU)1
1, 2TerminatedTreatmentMelanoma1
1, 2Unknown StatusTreatmentAcne Vulgaris1
2Active Not RecruitingTreatmentAneurysms1
2Active Not RecruitingTreatmentMarginal Zone Lymphoma of Ocular Adnexal1
2Active Not RecruitingTreatmentPain NOS1
2Active Not RecruitingTreatmentPrimary Systemic Amyloidosis1
2Active Not RecruitingTreatmentRosaceas1
2CompletedNot AvailableEye Dryness1
2CompletedBasic ScienceAortic Aneurysm, Abdominal1
2CompletedPreventionCardiopulmonary Bypass / Coronary Artery Bypass Graft Surgery Patients / Reperfusion Injury1
2CompletedPreventionCo-Infection / Mansonella Perstans Infection / Mycobacterium marinum infection / Tuberculosis Infection1
2CompletedPreventionRas-wildtype Colorectal Cancer1
2CompletedPreventionRash Due to Epidermal Growth Factor Receptor Inhibitors1
2CompletedSupportive CareAdvanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant1
2CompletedTreatmentAcne Vulgaris1
2CompletedTreatmentChronic Rhinosinusitis / Polyps, Nasal1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentDiabetic Foot Ulcers (DFU)1
2CompletedTreatmentBacterial blepharitis / Eye Dryness / Meibomianitis1
2CompletedTreatmentLeft Ventricular Remodeling / Myocardial Infarction1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMansonella Perstans Infection / Mp Microfilaremia1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentPelvic Inflammatory Disease (PID)1
2CompletedTreatmentPeriodontal Diseases / Periodontitis1
2CompletedTreatmentPeriodontitis, Chronic1
2CompletedTreatmentPosterior Blepharitis1
2CompletedTreatmentRetinopathy, Diabetic2
2CompletedTreatmentProphylaxis of cardiomyopathy / Transthyretin Amyloidosis1
2CompletedTreatmentTuberculosis Infection1
2CompletedTreatmentUrethritis1
2Not Yet RecruitingPreventionHeart Failure, Unspecified / ST Segment Elevation Myocardial Infarction (STEMI)1
2Not Yet RecruitingTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA) / Skin-structure infections1
2RecruitingTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2RecruitingTreatmentAtopic Dermatitis (AD)1
2RecruitingTreatmentCarcinoma, Breast / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Uterine Corpus Cancer / Uterine Corpus Carcinosarcoma1
2RecruitingTreatmentChlamydophila Pneumoniae Infections / Coronary Heart Disease (CHD)1
2RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) / Sezary Syndrome1
2RecruitingTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
2RecruitingTreatmentLarynx / LIP / Oral Cavity / Pharynx1
2RecruitingTreatmentMalignant Pleural Effusions1
2RecruitingTreatmentResectable Pancreatic Cancers1
2RecruitingTreatmentSeizures1
2RecruitingTreatmentSkin Toxicities1
2RecruitingTreatmentUlcerative Colitis (UC)1
2TerminatedTreatmentAdult Diffuse Large B-Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Malignant Lymphoma - Lymphoplasmacytic / Marginal Zone B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas / Waldenström's Macroglobulinemia (WM)1
2TerminatedTreatmentMinor Intra-uterine Abnormalities1
2TerminatedTreatmentNon-ischaemic Cardiomyopathy / Systolic Heart Failure (NYHA II-III)1
2TerminatedTreatmentPolyp of Nasal Sinus1
2Unknown StatusPreventionMucositis1
2Unknown StatusTreatmentAcne1
2Unknown StatusTreatmentAutoimmune Diseases / Endocrine System Diseases / Eye Diseases / Eye Diseases, Hereditary / Graves Diseases / Graves Ophthalmopathy / Hyperthyroidism / Immune System Diseases / Thyroid Diseases1
2Unknown StatusTreatmentPlague1
2, 3Active Not RecruitingTreatmentAcute Myocardial Infarction (AMI) / Cardiovascular Disease (CVD) / Vascular Diseases1
2, 3Active Not RecruitingTreatmentDry Macular Degeneration1
2, 3CompletedNot AvailableJarisch Herxheimer Reaction / Relapsing Fever, Tick-Borne1
2, 3CompletedTreatmentDiabetes Mellitus With Periodontal Disease1
2, 3Not Yet RecruitingTreatmentCardiac AL Amyloidosis1
2, 3Unknown StatusTreatmentAcne / Inflammatory Reaction1
2, 3Unknown StatusTreatmentEye Burns1
3CompletedNot AvailableMycoplasma Infections / Persian Gulf Syndrome1
3CompletedDiagnosticLyme Neuroborreliosis1
3CompletedSupportive CareMetastatic Cancers1
3CompletedTreatmentAcne1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAndrogen Excess / Menstrual Irregularities / Polycystic Ovarian Syndrome (PCOS)1
3CompletedTreatmentChlamydial Infections1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentLyme Disease2
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPeriodontitis1
3CompletedTreatmentPeriodontitis, Chronic1
3CompletedTreatmentReactive Arthritis / Reiter's Disease1
3CompletedTreatmentRosaceas1
3CompletedTreatmentSevere Acne Vulgaris1
3CompletedTreatmentSyphilis1
3CompletedTreatmentUrethritis1
3CompletedTreatmentUrogential Chlamydia Trachomatis Infection1
3CompletedTreatmentUterine Hemorrhage1
3Enrolling by InvitationTreatmentNeuroborreliosis, Borrelia Burgdorferi1
3Not Yet RecruitingTreatmentFilariasis / Lymphatic Filariasis / Lymphedema of the extremities1
3RecruitingTreatmentAcne Vulgaris1
3RecruitingTreatmentESI-related Bleeding1
3RecruitingTreatmentFilariasis / Lymphatic Filariasis / Lymphedema of the extremities2
3RecruitingTreatmentIndigestion1
3RecruitingTreatmentMalignancies / Overall Survival / Quality of Life1
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentTTR Cardiac Amyloidosis1
3TerminatedTreatmentAsthma Bronchial2
3Unknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3Unknown StatusTreatmentAlzheimer's Disease (AD)1
3Unknown StatusTreatmentMetastatic Colorectal Cancers / Skin Toxicities1
3Unknown StatusTreatmentScrub Typhus1
4Active Not RecruitingTreatmentAcne1
4CompletedBasic ScienceBacterial Infections1
4CompletedPreventionPregnancy Termination / Vomiting1
4CompletedSupportive CareRosaceas1
4CompletedTreatmentAcne1
4CompletedTreatmentAcne Vulgaris3
4CompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4CompletedTreatmentBorrelia Infection / Lyme Disease1
4CompletedTreatmentBorreliosis / Early Lyme Disease / Erythema Chronicum Migrans / Lyme Disease1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCoxiella Infection / Fatigue Syndrome, Chronic / Q Fever1
4CompletedTreatmentCystic Fibrosis (CF)1
4CompletedTreatmentErythema Chronicum Migrans / Post-Lyme Disease Symptoms1
4CompletedTreatmentFilarial; Infestation1
4CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
4CompletedTreatmentPapulopustular Rosacea (PPR)2
4CompletedTreatmentPeriodontal Diseases / Type 2 Diabetes Mellitus1
4CompletedTreatmentRosaceas3
4CompletedTreatmentSinusitis1
4CompletedTreatmentUrinary Bladder, Overactive1
4CompletedTreatmentBacterial blepharitis1
4Not Yet RecruitingTreatmentAnal infection / Chlamydia Trachomatis Infection / Vaginal Infections1
4RecruitingPreventionRabies1
4RecruitingTreatmentAnal chlamydia infection1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
4RecruitingTreatmentDry Eye Syndromes / Meibomian Gland Dysfunction (MGD)1
4TerminatedTreatmentBladder Pain Syndrome / Chronic Pelvic Pain Syndrome (CPPS)1
4TerminatedTreatmentPeriodontitis1
4TerminatedTreatmentSeptic Abortion1
4Unknown StatusTreatmentCervicitis / Chlamydia Trachomatis / Genital Mycoplasma Infection / Urethritis1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Inflammatory Reaction / Pulmonary Emphysema1
4Unknown StatusTreatmentEndometrial Bleeding / Periodontal Diseases1
4Unknown StatusTreatmentLyme Neuroborreliosis1
4WithdrawnPreventionCardiovascular Disease (CVD)1
4WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
Not AvailableActive Not RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Emphysema / Human Immunodeficiency Virus (HIV)1
Not AvailableActive Not RecruitingTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA)1
Not AvailableActive Not RecruitingTreatmentRosaceas1
Not AvailableCompletedNot AvailableErythema Chronicum Migrans1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableLyme Neuroborreliosis1
Not AvailableCompletedNot AvailableMycoplasma Pneumoniae1
Not AvailableCompletedNot AvailablePeriodontal Diseases / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedBasic ScienceCognitive Dysfunctions / Paresis / Paresthesia / Radicular Pain / Tiredness1
Not AvailableCompletedPreventionFirst Trimester Abortion1
Not AvailableCompletedPreventionMethicillin Resistant Staphylococcus Aureus Skin Infections1
Not AvailableCompletedPreventionOsteoarthritis (OA)1
Not AvailableCompletedPreventionSyphilis1
Not AvailableCompletedTreatmentAcne Vulgaris / Diet Modification1
Not AvailableCompletedTreatmentAortic Aneurysms1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentDiabetes Mellitus With Periodontal Disease1
Not AvailableCompletedTreatmentGastritis1
Not AvailableCompletedTreatmentOral Contraceptives (OC)1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableEnrolling by InvitationPreventionPropionibacterium1
Not AvailableNot Yet RecruitingNot AvailableSTIs Prevention1
Not AvailableRecruitingNot AvailableBullous Pemphigoid (BP)1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentAmyloidosis; Systemic1
Not AvailableRecruitingTreatmentMultiple Erythema Migrans1
Not AvailableRecruitingTreatmentPneumonia, Mycoplasma1
Not AvailableRecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingTreatmentTick-borne Encephalitis (TBE)1
Not AvailableTerminatedTreatmentAdvanced Cancers / Malignant Pleural Effusions1
Not AvailableTerminatedTreatmentUlcerative Colitis (UC)1
Not AvailableUnknown StatusTreatmentBreakthrough Bleeding1
Not AvailableUnknown StatusTreatmentLateral Epicondylalgia (Tennis Elbow)1
Not AvailableUnknown StatusTreatmentScrub Typhus1
Not AvailableUnknown StatusTreatmentSuspected Early Lyme Neuroborreliosis1
Not AvailableWithdrawnPreventionSeroma1
Not AvailableWithdrawnSupportive CareLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableWithdrawnTreatmentHeadache Disorders, Primary / Migraine Disorders / Migraine With Aura / Migraine Without Aura / Migraines / Migrainous Headache1
Not AvailableWithdrawnTreatmentRotator Cuff Injury1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Watson laboratories inc
  • Watson pharmaceuticals inc
  • Galderma laboratories lp
  • Rachelle laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pfizer laboratories div pfizer inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Pliva inc
  • Mayne pharma international faulding pharm
  • Warner chilcott bermuda ltd
  • Medicis pharmaceutical corp
  • Halsey drug co inc
  • Heather drug co inc
  • Interpharm inc
  • Private formulations inc
  • Ranbaxy pharmaceuticals inc
  • Superpharm corp
  • Warner chilcott div warner lambert co
  • West ward pharmaceutical corp
  • Teva pharmaceuticals usa inc
  • Collagenex inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Tolmar inc
  • Corepharma llc
  • Larken laboratories inc
  • Mutual pharmacal co
  • Truxton inc
  • Vintage pharmaceuticals inc
Packagers
  • Actavis Group
  • Acura Pharmaceutical Technologies Inc.
  • Advanced Pharmaceutical Services Inc.
  • Advanced Vision Research
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apace Packaging
  • Apical Pharmaceutical Corporation
  • Apotheca Inc.
  • Apothecon
  • APP Pharmaceuticals
  • Aqua Pharmaceuticals
  • A-S Medication Solutions LLC
  • Avidas Pharmaceuticals
  • Bedford Labs
  • Belgomex Sprl
  • Ben Venue Laboratories Inc.
  • Bioglan Pharmaceuticals Co.
  • Blenheim Pharmacal
  • Block Drug Corp.
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Bv Pharbita
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Catalent Pharma Solutions
  • Collagenex Pharmaceuticals Inc.
  • Community Action Inc. Community Health Services
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DSM Corp.
  • Eon Labs
  • Galderma Laboratories
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Hikma Pharmaceuticals
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mayne Pharma International Pty Ltd.
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Mississippi State Dept Health
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Oclassen Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Manufacturing Research Services Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmaderm
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Inc.
  • Tya Pharmaceuticals
  • Universal Laboratories Inc.
  • Veratex Corp.
  • Versapharm Inc.
  • Warner Chilcott Co. Inc.
  • Watson Pharmaceuticals
  • WC Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
CapsuleOral150 mg/1
TabletOral20 mg/1
KitOral50 mg/1
KitOral50 mg/500mg
Kit
Capsule, delayed release pelletsOral100 mg/1
Capsule, delayed release pelletsOral75 mg/1
Capsule, extended releaseOral100 mg
Tablet, delayed releaseOral120 mg/1
Tablet, delayed releaseOral60 mg/1
TabletOral100 mg
CapsuleOral40 mg/1
For suspensionOral25 mg/5mL
Injection, powder, lyophilized, for solutionIntravenous100 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous200 mg/20mL
Powder, for suspensionOral25 mg/5mL
Tablet, coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
CapsuleOral100 mg/1
CapsuleOral50 mg/1
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral50 mg/1
TabletOral100 mg/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral75 mg/1
Tablet, delayed releaseOral100 mg/1
Tablet, delayed releaseOral150 mg/1
Tablet, delayed releaseOral200 mg/1
Tablet, delayed releaseOral50 mg/1
Tablet, delayed releaseOral75 mg/1
Tablet, delayed releaseOral75 mg/100mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral100 1/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral20 mg/1
CapsuleOral75 mg/1
TabletOral150 mg/1
TabletOral50 mg/1
TabletOral75 mg/1
CapsuleOral50 mg/50mg
CapsuleOral100 mg/100mg
Kit50 mg/1
Kit100 mg/1
Capsule, delayed release pelletsOral40 mg/1
CapsuleOral20 mg
CapsuleOral100 mg
SyrupOral50 mg/5mL
PowderIntravenous100 mg
Prices
Unit descriptionCostUnit
Vibramycin 25 mg/5ml Suspension 60ml Bottle36.29USD bottle
Adoxa pak 1-150 mg tablet19.93USD tablet
Doryx 150 mg Enteric Coated Tabs17.51USD tab
Doryx dr 150 mg tablet16.83USD tablet
Doxycycline hyc 100 mg vial14.16USD vial
Adoxa 100 mg tablet13.86USD tablet
Monodox 100 mg capsule13.46USD capsule
Adoxa 75 mg tablet12.77USD tablet
Oracea 40 mg Delayed Release Capsule12.44USD capsule
Oracea 40 mg capsule11.96USD capsule
Avidoxy 100 mg tablet11.52USD tablet
Monodox 75 mg capsule11.02USD capsule
Doryx 100 mg Enteric Coated Tabs10.31USD tab
Doryx dr 100 mg tablet9.91USD tablet
Adoxa pak 1-100 mg tablet9.88USD tablet
Doxycycline Monohydrate 150 mg tablet9.51USD tablet
Adoxa 50 mg tablet9.29USD tablet
Doxycycline mono 150 mg tablet9.13USD tablet
Doryx 75 mg Enteric Coated Tabs8.76USD tab
Doryx dr 75 mg tablet8.42USD tablet
Vibramycin 100 mg capsule6.67USD capsule
Vibra-tabs 100 mg tablet6.67USD tablet
Monodox 50 mg capsule6.0USD capsule
Doxycycline mono 100 mg tablet5.98USD tablet
Periostat 20 mg tablet5.75USD tablet
Doxycycline mono 75 mg tablet5.74USD tablet
Doxycycline Monohydrate 100 mg tablet5.12USD tablet
Doxycycline mono 50 mg tablet4.17USD tablet
Doxycycline Monohydrate 50 mg tablet3.0USD tablet
Doxycycline hyclate powder2.56USD g
Vibramycin 50 mg capsule2.41USD capsule
Doxycycline Monohydrate 100 mg capsule2.22USD capsule
Vibramycin 100 mg Capsule1.91USD capsule
Doxycycline Monohydrate 50 mg capsule1.51USD capsule
Doxycycline hyclate 100 mg tablet1.28USD tablet
Doxycycline hyclate 20 mg tablet1.28USD tablet
Doxycycline Hyclate 100 mg capsule1.18USD capsule
Doxycycline Hyclate 50 mg capsule0.76USD capsule
Vibramycin 50 mg/5ml Syrup0.67USD ml
Vibramycin 50 mg/5 ml syrup0.64USD ml
Apo-Doxy 100 mg Capsule0.61USD capsule
Apo-Doxy 100 mg Tablet0.61USD tablet
Doxycin 100 mg Capsule0.61USD capsule
Doxycin 100 mg Tablet0.61USD tablet
Novo-Doxylin 100 mg Capsule0.61USD capsule
Novo-Doxylin 100 mg Tablet0.61USD tablet
Nu-Doxycycline 100 mg Capsule0.61USD capsule
Pms-Doxycycline 100 mg Capsule0.61USD capsule
Pms-Doxycycline 100 mg Tablet0.61USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6958161No2005-10-252022-12-15Us
US8715724No2014-05-062028-02-03Us
US7211267No2007-05-012022-04-05Us
US7232572No2007-06-192022-04-05Us
US7749532No2010-07-062027-12-19Us
US8206740No2012-06-262025-12-24Us
US8394405No2013-03-122024-04-07Us
US8394406No2013-03-122024-04-07Us
US8470364No2013-06-252024-04-07Us
US8603506No2013-12-102022-04-05Us
US5789395No1998-08-042016-08-30Us
US5919775No1999-07-062016-08-30Us
US8709478No2014-04-292024-04-07Us
US9241946No2016-01-262022-04-05Us
US9511031No2016-12-062034-10-23Us
US9446057No2016-09-202034-12-23Us
US9295652No2016-03-292034-10-23Us
US10058564No2002-04-052022-04-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)201 °CNot Available
water solubility630 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.02SANGSTER (1994)
logS-2.87ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.63 mg/mLALOGPS
logP-0.72ALOGPS
logP-3.3ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)2.93ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area181.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity113.89 m3·mol-1ChemAxon
Polarizability43.65 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.85
Blood Brain Barrier-0.9881
Caco-2 permeable-0.8706
P-glycoprotein substrateSubstrate0.699
P-glycoprotein inhibitor INon-inhibitor0.8038
P-glycoprotein inhibitor IINon-inhibitor0.8628
Renal organic cation transporterNon-inhibitor0.9562
CYP450 2C9 substrateNon-substrate0.8008
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6551
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorNon-inhibitor0.9293
CYP450 2C19 inhibitorNon-inhibitor0.9099
CYP450 3A4 inhibitorNon-inhibitor0.8567
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8086
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8632
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.3159 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9946
hERG inhibition (predictor II)Non-inhibitor0.7466
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Tetracyclines
Sub Class
Not Available
Direct Parent
Tetracyclines
Alternative Parents
Naphthacenes / Anthracenecarboxylic acids and derivatives / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Aralkylamines / Cyclohexenones / Tertiary alcohols / Vinylogous acids
show 9 more
Substituents
Tetracycline / Naphthacene / Tetracene / Anthracene carboxylic acid or derivatives / Tetralin / Aryl ketone / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Cyclohexenone / Aralkylamine
show 24 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
tetracyclines (CHEBI:50845) / Linear tetracyclines (C06973) / Linear tetracyclines (LMPK07000001)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
Gene Name
rpsI
Uniprot ID
P0A7X3
Uniprot Name
30S ribosomal protein S9
Molecular Weight
14856.105 Da
References
  1. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. [PubMed:20592239]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Translation repressor activity, nucleic acid binding
Specific Function
One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in trans...
Gene Name
rpsD
Uniprot ID
P0A7V8
Uniprot Name
30S ribosomal protein S4
Molecular Weight
23468.915 Da
References
  1. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. [PubMed:20592239]
3. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25. [PubMed:17428623]
  2. Kumar S, Kutlin A, Roblin P, Kohlhoff S, Bodetti T, Timms P, Hammerschlag MR: Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007 Feb;45(2):392-4. Epub 2006 Nov 22. [PubMed:17122017]
  3. Ross JI, Eady EA, Cove JH, Cunliffe WJ: 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998 Jul;42(7):1702-5. [PubMed:9661007]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein-arginine deiminase activity
Specific Function
Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone...
Gene Name
PADI4
Uniprot ID
Q9UM07
Uniprot Name
Protein-arginine deiminase type-4
Molecular Weight
74078.65 Da
References
  1. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13. [PubMed:17964793]
Details
5. Beta-2-microglobulin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
Gene Name
B2M
Uniprot ID
P61769
Uniprot Name
Beta-2-microglobulin
Molecular Weight
13714.43 Da
References
  1. Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, Codutti L, Salmona M, Mangione P, Colombo L, De Luigi A, Porcari R, Gliozzi A, Stefani M, Esposito G, Bellotti V, Stoppini M: Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem. 2011 Jan 21;286(3):2121-31. doi: 10.1074/jbc.M110.178376. Epub 2010 Nov 10. [PubMed:21068391]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Zhao XJ, Ishizaki T: A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8. [PubMed:10716067]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2018 13:38